kabutan

Heartseed Inc.(219A) Summary

219A
TSE Growth
Heartseed Inc.
1,833
JPY
+16
(+0.88%)
Apr 28, 3:30 pm JST
11.51
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
1,799.5
Apr 28, 9:40 pm JST
Summary Chart Historical News Financial Result
PER
PBR
5.83
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
1,808 JPY 11.34 USD
Previous Close Apr 27
1,817 JPY 11.39 USD
High Apr 28, 3:30 pm
1,833 JPY 11.51 USD
Low Apr 28, 9:21 am
1,803 JPY 11.31 USD
Volume
142,400
Trading Value
0.26B JPY 1.63M USD
VWAP
1819.73 JPY 11.43 USD
Minimum Trading Value
183,300 JPY 1,151 USD
Market Cap
0.04T JPY 0.26B USD
Number of Trades
601
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
High
1-Year Average
3,255
1-Year High Oct 2, 2025
50,688
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 533,900 1,556,600 2.92
Apr 17, 2026 753,200 1,515,200 2.01
Apr 10, 2026 771,700 1,518,300 1.97
Apr 3, 2026 677,800 1,631,700 2.41
Mar 27, 2026 684,900 1,722,300 2.51
Company Profile
Heartseed Inc. engages in the research and development of regenerative medicine products using iPS cells for cardiac regeneration.
Sector
Pharmaceuticals
Heartseed Inc. is a regenerative medicine venture originating from Keio University. The company is advancing the development of "cardiac regenerative medicine," a treatment method that involves transplanting micro-tissues (cardiac spheroids) derived from iPS cell-based cardiomyocytes into the heart, aiming to establish safety and efficacy. Heartseed possesses proprietary technologies, including techniques for producing high-purity cardiomyocytes and transplantation devices. With a vision for global expansion of cardiac regenerative medicine using allogeneic iPS cell-derived cardiac spheroids, the company entered into an exclusive worldwide technology partnership and licensing agreement with Novo Nordisk, a global pharmaceutical giant headquartered in Denmark, in May 2021.